Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 9419-9427

  Peng, Ling ^a   Bu, Zhibin ^a   Zhou, Yun ^b   Ye, Xianghua ^a   Liu, Junfang ^a   Zhao, Qiong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Food and Drug Administration   (China)

Author keywords

Aflibercept; Hemorrhagic events; Meta analysis

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ADVERSE DRUG REACTION; ADVERSE OUTCOME; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); ECCHYMOSIS; ENDOMETRIUM CANCER; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; GLIOMA; HEMATEMESIS; HEMATOTHORAX; HEMATURIA; HEMOPTYSIS; HUMAN; INCIDENCE; INJECTION SITE BLEEDING; INTRAOCULAR HEMORRHAGE; LUNG HEMORRHAGE; MELANOMA; MELENA; MENORRHAGIA; META ANALYSIS; METASTATIC COLORECTAL CANCER; METRORRHAGIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PETECHIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PURPURA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; VAGINA BLEEDING; BLEEDING; CHEMICALLY INDUCED; NEOPLASMS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEMORRHAGE; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; RISK FACTORS;

EID: 84919875443     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2189-1     Document Type: Article

References (28)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49.
3. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393–8.
4. Elice F, Rodeghiero F. Side effects of anti-angiogenic drugs. Thromb Res. 2012;129 Suppl 1:S50–3.
5. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13):2280–5.
6. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–37.
7. Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investig New Drugs. 2013;31(3):787–97.
8. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–71.
9. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.
10. Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, et al. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer. 2014;120(3):335–43.
11. Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154–62.
12. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506.
13. Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res. 2012;18(21):6023–31.
14. Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012;30(29):3640–7.
15. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol. 2010;5(7):1054–9.
16. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14(8):760–8.
17. Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013;49(12):2633–42.
18. Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, et al. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol. 2012;125(1):136–40.
19. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127(3):538–43.
20. Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17(20):6574–81.
21. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011;29(19):2689–95.
22. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010;76(4):923–6.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
24. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–91.
25. Kilickap S, Abali H, Bevacizumab CI. bleeding, thrombosis, and warfarin. J Clin Oncol. 2003;21(18):3542. author reply 3.
26. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–95.
27. Hang XF, Xu WS, Wang JX, Wang L, Xin HG, Zhang RQ, et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2011;67(6):613–23.
28. Qi WX, Tang LN, Sun YJ, He AN, Lin F, Shen Z, et al. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials. Ann Oncol. 2013;24(12):2943–52.